leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 12:57:27 - browse：18

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： What causes rare myocarditis in young men after Covid vaccines?

entertainment

WSS

'Investigate these claims': UFO transparency at center of House hearing

My daughter's legacy lives on through her writing, phage therapy

Medical device trials still don't enroll enough women, study finds

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Former reverend arrested for allegedly killing 8

Former reverend arrested for allegedly killing 8

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The cancer drug shortage isn’t new — and neither are the solutions

Cheap, fast test for Zika and dengue could cost just $1

Guidelines to prevent youth baseball injuries need more muscle

STAT Report: Patient voices and perspectives

How to save PrEP access — and even expand it

New report analyzes digital physical therapy solutions' effectiveness

The high cost of giving birth even with insurance

Rise in cancer among younger people worries and puzzles doctors

Medicare proposal to cover medical devices draws a mixed reaction

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

leisure time

Rise in cancer among younger people worries and puzzles doctors

Search called off for baby washed away in Pennsylvania flash flood

How faith leaders like me can help address America's obesity epidemic

Democrats decry new health bill for going easy on private equity

Teladoc has a new CEO, but challenges remain the same

Deposition: Sackler embraced plan to conceal OxyContin’s strength

focus

hotspot

entertainment

Wikipedia